Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Brouwer

Showing results (261-270 of 421) with videos related to

Pageof 43
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 13, 2017
Prediction of Clinically Relevant Herb-Drug Clearance Interactions Using Sandwich-Cultured Human Hepatocytes: <i>Schisandra spp.</i> Case StudyJonathan P Jackson, Kimberly M Freeman, Weslyn W Friley, et al.
Plos One|February 6, 2014
Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytesEve-Irene Lepist, Hunter Gillies, William Smith, et al.
Frontiers in Pharmacology|November 27, 2014
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injuryJeffrey L Woodhead, Kyunghee Yang, Scott Q Siler, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 16, 2004
Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteersA M Persky, C Ng, M H Song, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2013
Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIsN D Pfeifer, S L Goss, B Swift, et al.
Frontiers in Pharmacology|January 28, 2026
Development of an <i>in vitro</i> metabolic dysfunction-associated steatohepatitis model to investigate altered drug metabolizing enzymes, transport proteins, and hepatobiliary dispositionWilliam A Murphy, Sarina Kyburz, Henry Ho, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 16, 2011
Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic modelsGrace Zhixia Yan, Kim L R Brouwer, Gary M Pollack, et al.
Clinical Pharmacology and Therapeutics|December 23, 2017
Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 SubstrateIzna Ali, Jason R Slizgi, Josh D Kaullen, et al.
Molecular Pharmacology|September 9, 2006
The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in miceMaciej J Zamek-Gliszczynski, Ken-Ichi Nezasa, Xianbin Tian, et al.
Anesthesiology|March 2, 2018
Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy VolunteersJosh D Kaullen, Joel S Owen, Kim L R Brouwer, et al.
Pageof 43

Showing results (261-270 of 421) with videos related to

Sort By:
Pageof 43
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 13, 2017
Prediction of Clinically Relevant Herb-Drug Clearance Interactions Using Sandwich-Cultured Human Hepatocytes: <i>Schisandra spp.</i> Case StudyJonathan P Jackson, Kimberly M Freeman, Weslyn W Friley, et al.
Plos One|February 6, 2014
Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytesEve-Irene Lepist, Hunter Gillies, William Smith, et al.
Frontiers in Pharmacology|November 27, 2014
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injuryJeffrey L Woodhead, Kyunghee Yang, Scott Q Siler, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 16, 2004
Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteersA M Persky, C Ng, M H Song, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2013
Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIsN D Pfeifer, S L Goss, B Swift, et al.
Frontiers in Pharmacology|January 28, 2026
Development of an <i>in vitro</i> metabolic dysfunction-associated steatohepatitis model to investigate altered drug metabolizing enzymes, transport proteins, and hepatobiliary dispositionWilliam A Murphy, Sarina Kyburz, Henry Ho, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 16, 2011
Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic modelsGrace Zhixia Yan, Kim L R Brouwer, Gary M Pollack, et al.
Clinical Pharmacology and Therapeutics|December 23, 2017
Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 SubstrateIzna Ali, Jason R Slizgi, Josh D Kaullen, et al.
Molecular Pharmacology|September 9, 2006
The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in miceMaciej J Zamek-Gliszczynski, Ken-Ichi Nezasa, Xianbin Tian, et al.
Anesthesiology|March 2, 2018
Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy VolunteersJosh D Kaullen, Joel S Owen, Kim L R Brouwer, et al.
Pageof 43